Longtime Takeda R&D chief to depart next June—Chutes & Ladders
Longtime Takeda R&D chief to depart next June—Chutes & Ladders — latest biotechnology news.
Services: Global biopharma; gastroenterology, oncology, neuroscience, rare diseases, plasma-derived therapies; R&D-driven with AI/ML and lab automation. | Leadership: — | Keywords: global pharma, GI, oncology, rare diseases, plasma, Japan
Longtime Takeda R&D chief to depart next June—Chutes & Ladders — latest biotechnology news.
Takeda, Daiichi, Samsung Bio and more—Fierce Pharma Asia — latest pharmaceutical industry news.
Takeda's R&D chief Andy Plump to retire; Novo Nordisk appoints global research head — latest biopharma news.
Takeda’s long-term R&D head announces exit after major pipeline reorganization — latest biotech and pharma news.
Takeda has received FDA approval for Mimrylo, a first-in-class treatment for blood cancer. The approval strengthens Takeda's oncology portfolio with a novel mechanism of action.
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Takeda leads wave of orexin drugs with potential to upend narcolepsy market
Insilico inks partnership via $600M biobuck collab with Takeda — Fierce Biotech coverage of biopharma industry developments.
For the 2026 fiscal year, Takeda anticipates declines in revenue and profit, highlighting what CEO-elect Julie Kim says is the need for the company to “invest in future growth.”